Taking into account structure-activity relationships obtained with our previous series, new diversely substituted 1,2,4-pyridothiadiazine 1,1-dioxides were designed to obtain novel AMPA potentiators. The aim of this work was focused on the improvement of lipophilicity, which is well known as a critical parameter to obtain in vivo active central nervous system agents. For this purpose, two positions
考虑到我们以前的系列获得的结构活性关系,设计了新的,不同取代的1,
2,4-
吡啶并二嗪1,1-二
氧化物来获得新型
AMPA增效剂。这项工作的目的集中在改善亲脂性上,亲脂性是众所周知的获得体内活性中枢神经系统药物的关键参数。为此,
吡啶环上的两个位置被优先插入选定的基团。在合成的化合物中出现了7-
氯-4-乙基-3,4-二
氢-2H-
吡啶[2,3-e]-[1,
2,4]-噻二嗪1,1-二
氧化物(12d),在Wistar大鼠的两次记忆测试中进行了评估,结果显示腹腔注射低至0.3mg / kg的剂量后认知增强作用。